Exelixis
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 1.3K
- Market Cap
- $7.3B
- Website
- http://www.exelixis.com
- Introduction
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 28
- Registration Number
- NCT00475917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 49
- Registration Number
- NCT00464113
- Locations
- 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Study of XL418 in Adults With Solid Tumors
- Conditions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 63
- Registration Number
- NCT00460278
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Study of XL281 in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 180
- Registration Number
- NCT00451880
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
- Conditions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 30
- Registration Number
- NCT00350831
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00234481
- Locations
- 🇺🇸
UCSD Moores Cancer Center, San Diego, California, United States
🇺🇸City of Hope National Cancer Center, Duarte, California, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 85
- Registration Number
- NCT00215605
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of XL820 in Adults With Solid Tumors
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00129571
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States